Who Paid My Doc
A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels
Research payments
$697,153
Through program year 2024, $697,153 in research payments was reported against A Study to Evaluate Lumasiran in Adults With Recurrent Calcium Oxalate Kidney Stone Disease and Elevated Urinary Oxalate Levels, across 338 payments, paid by Alnylam Pharmaceuticals Inc..
- Paid by
- Alnylam Pharmaceuticals Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $104 | 2 |
| 2023 | Research | $304,514 | 157 |
| 2022 | Research | $392,479 | 177 |
| 2021 | Research | $56 | 2 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Theodore Manny Greensboro, NC Named on 65 payments
- Mitchell Efros Garden City, NY Named on 39 payments
- David Goldfarb New York, NY Named on 21 payments
- Mark Vishnepolsky Las Vegas, NV Named on 17 payments
- Chinedu Nweke Douglasville, GA Named on 16 payments
- Daniel Schneider Memphis, MO Named on 16 payments
- Jonathan Tolins Edina, MN Named on 14 payments
- Ronald Ralph Houston, TX Named on 11 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.